Professionals 227 Users Online

Alopecia Treatment Market

Rising alopecia-related therapies across the globe are driving the demand for the Alopecia Treatment Market

Alopecia Treatment Market by Type (Topical Drugs, Oral Drugs, Injectable, Hair Transplant Services and Low-Level Laser Therapy)

Alopecia Treatment Market Outlook (2023 to 2033 )

Worldwide revenue from the Alopecia Treatment Market was about US$ 9.2 Billion in 2022, with the global market estimated to surge ahead at a CAGR value of 9.1% to reach a valuation of US$ 24.0 Billion by the end of 2033.

Alopecia Treatment Market Size (2022)

US$ 9.2 Billion

Projected Market Value (2033)

US$ 24.0 Billion

Global Market Growth Rate (2023 to 2033 )

5.6% CAGR

Market Share of Top 5 Countries


As assessed by Persistence Market Research, alopecia treatment products are expected to hold a market value of US$ 24.0 Billion by 2033. Overall, market sales account for approximately 66.9% of revenue share in the global hair loss treatment market, which was valued at around US$ 13.7 Billion in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Alopecia Treatment from 2012 to 2021 Vs Market Outlook for 2022 to 2033

The Global Market for Alopecia Treatment recorded a historic CAGR of 7.0% in the last 9 years from 2014 to 2022.

Alopecia is a common autoimmune condition that causes hair loss all over the body, primarily on the scalp. Alopecia areata, the most common kind, typically begins as one or more tiny circular patches on the scalp and develops to total hair loss on the scalp or entire body (Aalopecia universalis). The market for treating alopecia has grown as a result of consumer demand for hair-restoration medications, many of which have increased efficacy and few negative effects. For instance, in the domain of treating alopecia, cutting-edge therapies like cytokine therapy and regenerative cell therapy are gaining popularity.

Less than 5% of all people with alopecia have Alopecia universalis, the least common autoimmune condition. Extensive alopecia is difficult to control, and occasionally, patients may not benefit from treatment. Over the course of the forecast period, the hair loss industry's market landscape is expected to be characterized by an increased focus on the provision of hair loss solutions (with both functional and active ingredients) with multifunctional effects, as well as by an increase in the penetration of cutting-edge hair loss treatment therapies like stem cell therapy.

The number of people treated for hair loss is anticipated to increase with the advent of low-level laser therapy, which helps encourage hair growth. Additionally, the advent of laser hats, helmets, combs, and bands is anticipated to spur market expansion.

One of the main factors propelling the market expansion is the rise in the prevalence of alopecia treatments. The American Academy of Dermatology Association (AAD) reported that 50 million Americans, including more than 50 million men and 30 million women, were anticipated to be affected by alopecia in 2018.

According to research published in The Journal of Clinical and Diagnostic Research (JCDR), pattern hair loss affects around 60% of the population, with different factors affecting how severe it is in both sexes.

The global market is thus likely to show high growth over the coming years a CAGR value of 9.1% and reach a global market size of US$ 24.0 Billion by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can Manufacturers of the Alopecia Treatment Product Grow?

Rising global demand for effective hair loss treatment medications– Transforming Alopecia Treatment Sector

Greater awareness of physical well-being, an increase in the prevalence of cancer and other skin-related problems, changing hairstyles, increased alcohol usage, and rising stress levels have all contributed to an increase in the demand for effective medications. This has increased the need for and the supply of efficient hair loss treatment regimens. It is thought that medications like propecia reduce the level of a naturally occurring body hormone (DHT). Increased hair regrowth and slower hair loss result from lowering DHT levels. Management of alopecia with cytokines is gaining traction in a billion-dollar alopecia treatment market. Cytokine therapy has proven to be one of the effective treatments for differentiation and proliferation of hair follicles, while controlling hair growth cycle.

For example,

  • In Aug 2021, Pfizer Inc. announced the positive results of Phase 2b 3 ALLEGRO, which evaluated an oral once-a-day Ritlecitinib drug in patients with alopecia areata, an autoimmune disease characterized by the hair loss on the scalp and can also affect the face and body.

The introduction of these new technologies is expected to result in high adoption rates, which will in turn drive market growth during the forecast period.

Manufacturers are also devoting more resources to research and development in order to introduce more cost-effective and advanced technology. Key companies' increased research and development operations will soon result in the introduction of new technologies. These factors are expected to improve the acceptance of the hair loss therapies for alopecia, resulting in market growth throughout the forecast period.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Can Demand for Alopecia Treatment Product Be Affected in Any Way?

“Limited efficacy of existing hair loss treatment drugs ”

Global market expansion is being hampered by a lack of data demonstrating the therapeutic efficacy of the available hair loss medications. As consumers become more knowledgeable about the clinical efficacies of products and the sustainability of treatment effectiveness, this factor could negatively impact market share and revenue growth for well-established items.

For instance, despite being clinically proved to reduce the rate of hair loss, topical hair loss therapies now on the market, such as minoxidil, are not 100% successful in treating alopecia. The majority of knowledgeable hair loss treatment professionals consider it to be a medicine with only moderately effective against hair loss. FDA-approved minoxidil has no impact on the hormonal cause of hair loss, and it typically produces temporary results.

Additionally, the majority of laser treatment services are not covered by public or private payers. This tendency, which has a considerable impact on service acceptance in these regions, is particularly noticeable in important nations in the Asia Pacific and MEA. The prices of the services also vary, which could have an impact on how fast the worldwide market expands.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the United States Market Booming?

“Increasing U.S.FDA Approvals of New Drugs”

The United States accounted for more than 92.2% market share in the North America alopecia treatment market in 2022, and a similar trend is expected over the forecast period.

Unpredictable hair loss is a common symptom of the autoimmune disease alopecia areata. An estimated 6.8 million Americans are impacted by it. Men and women are equally affected by alopecia areata, and it can affect anyone from any ethnic origin. Furthermore, it is anticipated that the region's sophisticated healthcare infrastructure, coupled with stringent Alopecia Treatment criteria, will hasten the development of the market in the nation.

One in 500 to one in 1,000 Americans, according to the United States National Library of Medicine, suffer from alopecia areata. Alopecia areata, one of the numerous identified types of alopecia, is the second most prevalent kind after androgenetic alopecia. As a result, the U.S. has a high prevalence of hair loss and proportionally high treatment rates, which are important growth factors for the North American industry. Many big players are coming up with new drugs and therapies. For Instance-

The first systemic treatment for alopecia areata is baricitinib oral pills, which were created by Eli Lilly and authorized by the U.S. Food and Drug Administration (FDA) in October 2022.

Will Germany Be a Lucrative Market for Alopecia Treatment Product And Service Providers?

“High Adoption Rate of New Advanced Technologies”

Germany held around 26.8% market share of the Europe market in 2022.

Germany continues to be the European Union's second-largest manufacturer of active biopharmaceutical products. According to health department statistics from Europe, urban people are using 30% more hair care products than they were five years ago, which is predicted to boost demand for hair restoration and transfiguration goods. The market players have a tonne of opportunity as platelet-rich plasma therapy becomes more widely used. For instance, in April 2020, experts from the Department of Plastic and Reconstructive Surgery at the "Tor Vergata" University in Italy reported that platelet-rich plasma is regarded as a safe and effective alternative to Minoxidil and Finasteride to cure hair loss.

How is China Emerging as a Prominent Market for Alopecia Treatment?

“High Adoption Rate of Organic Products and Herbal Oils in China”

China held the largest market share of about 49.3% of the East Asia market in 2022.

One in six Chinese adults, or over 250 million people, experience hair loss, according to a 2019 poll published by the China Association of Health Promotion and Education (CAHEP). According to the Journal of Clinical and Diagnostic Research (JCDR), pattern hair loss is the most common type of hair loss in both men and women, affecting about 60% of the population. Additionally, alopecia treatment (hair loss) is highly likely to develop in about 2% of the general population, regardless of gender. As a result of the widespread baldness of males in China, which is referred to as a "bald wave," a lucrative new market for hair loss treatments has emerged. The adoption of organic hair products and herbal oils is also very high in India and China. Due to their greater susceptibility to hair loss, men are more inclined to promote organic hair loss products. Hence Chinese market is expected to grow over the forecast period.

Category-wise Insights

Which Treatment Type is Driving the Growth of the Global Market?

“High Demand for Development and Manufacturing of Oral Drugs across Regions”

The oral drugs segment held around 37.1% share in the overall market in 2022.

Factors such as the growing number of biotechnology and life science companies in developed regions (North America and Europe) and the growing demand for the development and manufacturing of biological products increase the growth of drugs. Doctors recommend oral corticosteroids for patients who are losing their hair quickly and extensively. Oral medicine is reasonably priced but may have some negative effects.

Which End User Settings Pose a Greater Adoption of Alopecia Treatment Products and Services?

“Comfort and Privacy of a Doctor's Office”

Dermatologic and trichology clinics hold a larger share of about 41.1% with a market value of around US$ 3.4 Billion in 2022. People especially Asian favor dermatology and trichology clinics for hair loss therapy primarily because hospitals cannot match the comfort and privacy of a doctor's office. In addition, the penetration of private clinics has grown significantly over the past five years in countries like Japan, China, South Korea, and Malaysia. This has had a positive effect on service provider pricing, elevating the market for hair loss treatment. Dermatology offices are updated with the newest diagnostic tools and medical professionals skilled in the targeted treatment fields.

Competitive Landscape

To strengthen their product lines around the globe, leading manufacturers are developing technologically advanced products. Similarly, several major competitors in the alopecia treatment industry have engaged in consolidation activities such as mergers and acquisitions. Another significant approach noticed in the industry is the expansion of corporate collaborations in order to boost their alopecia treatment services.

For instance:

  • In Aug 2021, Pfizer Inc. announced the positive results of Phase 2b 3 ALLEGRO, which evaluated an oral once-a-day Ritlecitinib drug in patients with alopecia areata, an autoimmune disease characterized by hair loss on the scalp and can also affect the face and body.
  • The Food and Drug Administration (FDA) authorized the use of the drug baricitinib (Olumiant) in June 2022 to treat extreme cases of alopecia areata. It is the first systemic therapy for alopecia that the FDA has approved. This kind of systemic therapy aids in treating body-wide hair loss. Elli Lilly and Company is granted approval.

Alopecia Treatment Industry Report Scope



Forecast Period

2023 to 2033

Historical Data Available for

2014 to 2022

Market Analysis

USD Billion for Value

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC
  • North Africa
  • South Africa

Key Market Segments Covered

  • Treatment
  • End-User
  • Region

Key Companies Profiled

  • Elli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Johnson & Johnson, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Cipla Ltd.
  • Cellmid Ltd.
  • The Himalaya Drug Company
  • Taisho Pharmaceutical Holdings Co., Ltd
  • Shiseido Co., Ltd.
  • Zhangguang 101 Science & Technology Co., Ltd.
  • Pfizer
  • Thera dome
  • Curallux

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Alopecia Treatment Industry Research

By Treatment Type:

  • Topical Drugs
    • Creams
    • Oils
    • Gels
    • Shampoo
    • Lotion
    • Foam
  • Oral Drugs
  • Injectable
    • Platelet Rich Plasma
    • Steroid Injections
    • Injectable Filler
  • Hair Transplant Services
  • Low-Level Laser Therapy

By End User:

  • Hospitals
  • Dermatologic and Trichology Clinics
  • Home care settings
  • Aesthetic Clinics

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Elli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Johnson & Johnson, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Cipla Ltd.
  • Cellmid Ltd.
  • The Himalaya Drug Company
  • Taisho Pharmaceutical Holdings Co., Ltd
  • Shiseido Co., Ltd.
  • Zhangguang 101 Science & Technology Co., Ltd.
  • Pfizer
  • Thera dome
  • Curallux

- Frequently Asked Questions -

The global alopecia treatment market is currently valued at around US$ 9.2 Billion in 2022.

Sales of the alopecia treatment market are set to witness a high growth rate of 9.1% and be valued at US$ 24.0 Billion by 2033.

Demand for the alopecia treatment market increased at 7.0% CAGR from 2014 to 2022.

The U.S., Germany, U.K., China, and India account for most demand for alopecia treatment, currently holding 69.0% market share.

The U.S. accounts for around 92.2% share of the North American market.

Elli Lilly and Company, Teva Pharmaceutical Industries Ltd., and Merck & Co., Inc. are the top three manufacturers of alopecia treatment products.

The China market held a share of about 49.3% in the East Asia alopecia treatment market in 2022, while India accounts for around 44.6% share.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate